NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...
"The development of the Teoxane RHA ® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," states Valérie Taupin, Founder and CEO of Teoxane. "Mepivacaine represents the first ...
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational ...
According to the terms of the deal, Crown will buy Revance at $3.65 per share At the closing, Revance will no longer trade on the Nasdaq Revance’s portfolio includes Daxxify for injection and the RHA ...
Pittsburgh's leading med spa offers resilient hyaluronic acid fillers designed to adapt to facial movements while delivering natural-looking results. PITTSBURGH, PA, UNITED STATES, May 19, 2025 ...
Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback